ELEANOR SEGAL

LOS ALTOS, CA

General Payments — all program years on this page

$33,900.00

  • Category: General Payments
  • Program years: PY2018–2019
  • Record count: 20
  • As of (CMS publication): 2026-01-23

Latest program year (PY2019): $19,800.00 across 14 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2019) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $19,800.0014

By paying entity

Latest program year (PY2019) · sorted by reported total.

Paying entityAmountRecords
Actelion Pharmaceuticals US, Inc. $19,800.0014

By program year

Program yearAmountRecords
2018 $14,100.006
2019 $19,800.0014

Records — PY2019 (14)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
659787745 Actelion Pharmaceuticals US, Inc. $1,350.00 01/11/2019 Consulting Fee Undisputed 01/23/2026 View at CMS
659787759 Actelion Pharmaceuticals US, Inc. $900.00 02/13/2019 Consulting Fee Undisputed 01/23/2026 View at CMS
659787767 Actelion Pharmaceuticals US, Inc. $975.00 03/18/2019 Consulting Fee Undisputed 01/23/2026 View at CMS
659787775 Actelion Pharmaceuticals US, Inc. $750.00 04/05/2019 Consulting Fee Undisputed 01/23/2026 View at CMS
659787785 Actelion Pharmaceuticals US, Inc. $2,250.00 05/08/2019 Consulting Fee Undisputed 01/23/2026 View at CMS
659787793 Actelion Pharmaceuticals US, Inc. $750.00 06/10/2019 Consulting Fee Undisputed 01/23/2026 View at CMS
659787797 Actelion Pharmaceuticals US, Inc. $375.00 07/04/2019 Consulting Fee Undisputed 01/23/2026 View at CMS
659787811 Actelion Pharmaceuticals US, Inc. $450.00 08/09/2019 Consulting Fee Undisputed 01/23/2026 View at CMS
659787827 Actelion Pharmaceuticals US, Inc. $450.00 10/18/2019 Consulting Fee Undisputed 01/23/2026 View at CMS
659787831 Actelion Pharmaceuticals US, Inc. $3,075.00 10/18/2019 Consulting Fee Undisputed 01/23/2026 View at CMS
659796043 Actelion Pharmaceuticals US, Inc. $450.00 10/18/2019 Consulting Fee Undisputed 01/23/2026 View at CMS
659796047 Actelion Pharmaceuticals US, Inc. $3,075.00 10/18/2019 Consulting Fee Undisputed 01/23/2026 View at CMS
659796051 Actelion Pharmaceuticals US, Inc. $375.00 11/11/2019 Consulting Fee Undisputed 01/23/2026 View at CMS
659796053 Actelion Pharmaceuticals US, Inc. $4,575.00 12/10/2019 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2019_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.